Ann: Appendix 4E and Annual Report to Shareholders, page-17

First 17 Last

Share
Profile

Follow
GrimWally

1,285 Posts.

45

25/08/17

07:53

Post #: 26745807
Share

Originally posted by oggede ↑

$3m is peanuts for a global growing SaaS company. Just lol if you think that's gonna last more than a few months. Overheads are currently $6m per year and are likely going higher. Also, 'you're dreaming' if you think those options are going to get converted at 6 cents next year.

I wouldn't be surprised if they have been shopping around for funds lately on the back of the run up to 2 cents. That's probably why the stock is down as the big boys have been selling and are getting ready to reload. My bet is a raise at 1.3 before Xmas, if they're lucky.

Every start up today has a management team with key stake holdings. However, if you look at the past history most have personal holdings that have been offloaded or private trades before listing - not to mention their salaries. Of course they want this to succeeded, what else are they gonna do.

It's the perfect comparison to GeoOp. Both have limited appeal and are examples of over complicated, unnecessary, and cumbersome software. It's as if they just wanted to "cloud" something for the sake of it. They're struggling to sell this, and are constantly trying to find new ways to package it. Maybe they'll find a niche industry where it might work but the thought of this becoming mainstream is a joke.

Answer to El Jefe, yes I meant R & D refund, which is classified as other revenue, which is excluded from year on year comparison.

Expand

They struggled to sell prior to this year as they didn't have the adequate sales team to do so. Things are changing!

VPC Price at posting: 1.8¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial